Depression Clinical Trial
Official title:
Program ACTIVE II: Behavioral Depression Treatment for Type 2 Diabetes
Verified date | December 2017 |
Source | Indiana University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Program ACTIVE II is a depression treatment study sponsored by the National Institutes of Health, Indiana University, Ohio University and West Virginia University. The purpose of this study is to test the effectiveness of two forms of treatment for depression for adults with type 2 diabetes: talk therapy (counseling) and exercise. Both of these forms of treatment have been proven to be effective in helping people with depression alone. In this study, the investigators will test to see if both of these approaches may be more effective in helping people live depression-free compared to talk therapy, exercise or usual care alone.
Status | Completed |
Enrollment | 140 |
Est. completion date | July 31, 2017 |
Est. primary completion date | June 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - able to walk without the use of a cane or walker - diagnosis of type 2 diabetes for at least one year duration or longer - major depression lasting two weeks or longer Exclusion Criteria: - history of diabetic ketoacidosis (DKA) - history of continuous insulin therapy since diabetes diagnosis - stage 2 hypertension as defined by JNC VII - recent cardiac events (e.g., unstable angina, diagnosed angina, PTCA, any cardiac intervention for CAD or tachydysrhythmias in the past six months) - laser surgery for proliferative retinopathy in the past six months - history of stroke, lower limb amputation, asensory peripheral neuropathy, aortic stenosis or other sever valvular heart disease, atrial fibrillation, severe COPD (e.g., basal oxygen), class III or IV heart failure - active suicidal ideation or history of suicide attempt - history of bipolar disorder - history of psychotic disorder - current substance abuse or dependence disorder - individuals who report the use of a current antidepressant medication for five weeks or less were excluded or deferred for later screening after the 6 week period - individual who were receiving psychotherapy from a mental health provider for depression were excluded |
Country | Name | City | State |
---|---|---|---|
United States | Ohio University | Athens | Ohio |
United States | Indiana University | Indianapolis | Indiana |
United States | West Virginia University | Morgantown | West Virginia |
Lead Sponsor | Collaborator |
---|---|
Indiana University | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Ohio University, University of Michigan, West Virginia University |
United States,
de Groot M, Crick KA, Long M, Saha C, Shubrook JH. Lifetime Duration of Depressive Disorders in Patients With Type 2 Diabetes. Diabetes Care. 2016 Dec;39(12):2174-2181. Epub 2016 Oct 11. — View Citation
de Groot M, Shubrook J, Schwartz F, Hornsby WG Jr, Pillay Y, Saha C. Program ACTIVE II: Design and Methods for a Multi-Center Community-Based Depression Treatment for Rural and Urban Adults with Type 2 Diabetes. J Diabetes Res Ther. 2015 Aug;1(2). doi: 10.16966/2380-5544.108. Epub 2015 Aug 5. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in HbA1c | Based on our pilot data, mean glycemic control (as measured by HbA1c) is expected to improve .4% in participants in the EXER and CBT + EXER treatment conditions at POST compared to baseline (de Groot et al., 2009). Participants assigned to the CBT + EXER treatment are expected to show the greatest improvement in HbA1c followed by those in the EXER group in comparison to the CBT group. No improvement is expected among those assigned to the UC condition. | following completion of intervention (~3 months), 6-months following completion of intervention, and 12-months following completion of intervention | |
Primary | Change in depression status - Beck Depression Inventory | Participants in the CBT, EXER and CBT + EXER conditions will show clinically significant improvements in BDI at POST, 6- and 12-month assessments with the greatest improvements expected among those in CBT + EXER condition. Based on pilot data, severity of depression, as measured by the BDI-II, will significantly decrease from baseline to POST and baseline to follow-up assessments, after co-varying the effect of gender, number of T2DM complications, and exposure to treatment. | following completion of intervention (~3 months), 6-months following completion of intervention, and 12-months following completion of intervention | |
Primary | Change in depression status - Diagnosis of Major Depressive Disorder | Participants in the CBT, EXER and CBT + EXER conditions will show clinically significant improvements in diagnosis of MDD at POST, 6- and 12-month assessments with the greatest improvements expected among those in CBT + EXER condition. Based on pilot data, a) a 66% reduction in the number of people who meet DSM-IV criteria for MDD is expected at POST compared to baseline; b) 86-90% percent of cases with MDD remission at POST are expected to remain remitted at the 6-month follow-up, after co-varying the effect of gender, number of T2DM complications, and exposure to treatment. It is anticipated that participants in the CBT + EXER condition will show the longest remission rates of depression followed by those in EXER and CBT. | following completion of intervention (~3 months), 6-months following completion of intervention, and 12-months following completion of intervention | |
Secondary | Changes in cardiovascular (CVD) risk factors | Changes in CVD risk factors in the intervention groups compared to UC over time. Physical activity capacity, as measured by the 6-minute walk test (6MWT), will demonstrate the greatest improvements in the CBT + EXER arm, closely followed by the EXER arm at follow-up assessment compared to baseline. Participants in the CBT and UC arms are not expected to show significant improvements. LDL-C is expected to improve at POST in the EXER and CBT + EXER conditions, consistent with pilot data. | following completion of intervention (~3 months), 6-months following completion of intervention, and 12-months following completion of intervention | |
Secondary | Cost effectiveness analyses | The cost of predicted incidence of complications, particularly coronary heart disease (CHD), will be lower among those who receive the CBT + EXER condition compared to the CBT, EXER and UC conditions. Further, the costs of this intensive intervention will be offset by a decrease in complication incidence. | following completion of intervention (~3 months), 6-months following completion of intervention, and 12-months following completion of intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A |